TABLE 5.

Pharmacological profile of P2X5R

EC₅₀/IC₅₀ values are micromolar unless otherwise specified.

Compound	Method	EC50/IC50	References
Full agonists
ATP	Current	0.5–4	Wildman et al., 2002; Bo et al., 2003
2-meSATP	Current	0.5	Wildman et al., 2002
ATPγS	Current	0.5	Wildman et al., 2002
Partial agonists
αβ-meATP	Current	1–12	Wildman et al., 2002; Kotnis et al., 2010
βγ-meATP	Current	10	Wildman et al., 2002
BzATP	Current	1–6	Wildman et al., 2002; Bo et al., 2003
Ap3A	Current	5	Wildman et al., 2002
Ap4A	Current	0.3	Wildman et al., 2002
Ap5A	Current	0.7	Wildman et al., 2002
Ap6A	Current	5	Wildman et al., 2002
Antagonists
Suramin	Current	2–3	Wildman et al., 2002; Bo et al., 2003
PPADS	Current	200–600 nM	Wildman et al., 2002; Bo et al., 2003; Kotnis et al., 2010
TNP-ATP	Current	600–700 nM	Wildman et al., 2002; Kotnis et al., 2010
BBG	Current	0.5	Bo et al., 2003
Modulators
Protons (−)	Current		Wildman et al., 2002
Calcium (−)a	Current	10 mM	Wildman et al., 2002
Zinc (+)b	Current	10	Wildman et al., 2002

(+), positive modulator; (−), negative modulator.

^a In addition, a sensitization of ATP-evoked currents is observed with calcium.

^b Biphasic effects, suggesting the existence of more than one allosteric site.